ProQR Therapeutics N.V. (PRQR) to Release Quarterly Earnings on Monday

ProQR Therapeutics N.V. (NASDAQ:PRQR) will announce its earnings results before the market opens on Monday, November 13th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter.

ProQR Therapeutics N.V. (PRQR) opened at $3.55 on Friday. ProQR Therapeutics N.V. has a fifty-two week low of $3.55 and a fifty-two week high of $6.90. The company has a current ratio of 8.22, a quick ratio of 8.22 and a debt-to-equity ratio of 0.17.

A number of research analysts have recently issued reports on PRQR shares. Zacks Investment Research downgraded ProQR Therapeutics N.V. from a “buy” rating to a “hold” rating in a report on Tuesday, August 29th. ValuEngine upgraded ProQR Therapeutics N.V. from a “sell” rating to a “hold” rating in a report on Friday, September 15th. JMP Securities boosted their target price on ProQR Therapeutics N.V. from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 26th. Finally, Chardan Capital restated a “neutral” rating on shares of ProQR Therapeutics N.V. in a research note on Sunday, September 17th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $19.38.

TRADEMARK VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at

ProQR Therapeutics N.V. Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.

Earnings History for ProQR Therapeutics N.V. (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with's FREE daily email newsletter.

Leave a Reply